AAPGV Stock Price, Chart, Stats & News

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR-ABL1 mutants, notably those harboring the T315I mutation. The company's extensive pipeline further comprises: APG-2575, an orally administered, selective Bcl-2 inhibitor for hematologic malignancies and solid tumors.